Revenue Breakdown
Composition ()
No data
Revenue Streams
Transmedics Group Inc (TMDX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is OCS Liver net revenue, accounting for 75.7% of total sales, equivalent to $107.94M. Other significant revenue streams include OCS Heart net revenue and OCS Lung net revenue. Understanding this composition is critical for investors evaluating how TMDX navigates market cycles within the Advanced Medical Equipment & Technology industry.
Profitability & Margins
Evaluating the bottom line, Transmedics Group Inc maintains a gross margin of 58.11%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 13.23%, while the net margin is 65.55%. These profitability ratios, combined with a Return on Equity (ROE) of 54.24%, provide a clear picture of how effectively TMDX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, TMDX competes directly with industry leaders such as LNTH and CELC. With a market capitalization of $5.04B, it holds a leading position in the sector. When comparing efficiency, TMDX's gross margin of 58.11% stands against LNTH's 59.21% and CELC's N/A. Such benchmarking helps identify whether Transmedics Group Inc is trading at a premium or discount relative to its financial performance.
